Table 3.
Convenience attributes | Scoring | ||||
---|---|---|---|---|---|
Cladribine tablets | Fingolimod | Natalizumab | Ocrelizumab | Alemtuzumab | |
Convenient route and dosing schedule | 8.7 | 8.0 | 7.5 | 7.8 | 8.1 |
Good patient compliance | 8.0 | 7.3 | 8.0 | 7.8 | 8.3 |
Low monitoring burden | 8.0 | 6.7 | 7.5 | 7.2 | 5.9 |
DMD disease-modifying drug